Our top pick for
Akouos, Inc is a biotechnology business based in the US. Akouos shares (AKUS) are listed on the NASDAQ and all prices are listed in US Dollars. Akouos employs 54 staff and has a market cap (total outstanding shares value) of USD$699.7 million.
|Latest market close||USD$19.91|
|52-week range||USD$16.59 - USD$30.67|
|50-day moving average||USD$19.344|
|200-day moving average||USD$21.0765|
|Wall St. target price||USD$33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.932|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||9.10%|
|1 month (2020-12-18)||7.51%|
|3 months (2020-10-19)||1.69%|
|6 months (2020-07-17)||-5.73%|
|1 year (2020-01-16)||N/A|
|2 years (2019-01-16)||N/A|
|3 years (2018-01-16)||N/A|
|5 years (2016-01-16)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$699.7 million|
TTM: trailing 12 months
There are currently 1.6 million Akouos shares held short by investors – that's known as Akouos's "short interest". This figure is 2.2% down from 1.6 million last month.
There are a few different ways that this level of interest in shorting Akouos shares can be evaluated.
Akouos's "short interest ratio" (SIR) is the quantity of Akouos shares currently shorted divided by the average quantity of Akouos shares traded daily (recently around 90190.213010938). Akouos's SIR currently stands at 17.37. In other words for every 100,000 Akouos shares traded daily on the market, roughly 17370 shares are currently held short.
However Akouos's short interest can also be evaluated against the total number of Akouos shares, or, against the total number of tradable Akouos shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akouos's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Akouos shares in existence, roughly 50 shares are currently held short) or 0.0604% of the tradable shares (for every 100,000 tradable Akouos shares, roughly 60 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Akouos.
Find out more about how you can short Akouos stock.
We're not expecting Akouos to pay a dividend over the next 12 months.
Akouos, Inc., a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.